Findings

What do systematic reviews say?

8 questions · 8 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 4 · 50%Low 1 · 12.5%Moderate 2 · 25%High 1 · 12.5%

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of FLU changes mortality: 10 weeks compared with two weeks of 5FC + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.46 [0.96, 2.23]
2 studies · 98 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + 5FC (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.92 [0.69, 1.23]
1 study · 340 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of 5FC + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (moderate certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.85 [0.64, 1.13]
1 study · 339 participants
Moderate

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd (low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.94 [0.55, 1.62]
3 studies · 371 participants
Low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + 5FC (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 2.81 [0.33, 24.16]
1 study · 31 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd + FLU (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 0.43 [0.13, 1.37]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

It is very uncertain whether two weeks of AmBd + 5FC + FLU changes mortality: 10 weeks compared with two weeks of AmBd (very low certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1 [0.24, 4.23]
1 study · 32 participants
Very low

Mortality: 10 weeks · HIV‐infected individual with first episode of cryptococcal meningitis

Two weeks of AmBd + FLU + steroids showed no clear difference in mortality: 10 weeks compared with two weeks of AmBd + FLU (high certainty).

1 finding from 1 review

Treatment for HIV‐associated cryptococcal meningitis 2018 · Cochrane Headline outcomes only
RR 1.15 [0.93, 1.42]
1 study · 450 participants
High